The MERITO Study: A multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during 'titration phase' in patients with cancer pain

Palliative Medicine

Volumn 22, Issue 3, 2008, Pages 214-221

  De Conno, Franco ^a   Ripamonti, Carla Ida ^a   Fagnoni, Elena ^a   Brunelli, C ^a   Luzzani, M ^b   Maltoni, Marco ^c   Arcuri, Edoardo ^d   Bertetto, Oscar ^e  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Ospedale Civile di Forlimpopoli Dip   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e MOLINETTE HOSPITAL   (Italy)

Author keywords

Cancer pain; Morphine; Normal release; Oral; Tolerability

Indexed keywords

ANALGESIC AGENT; COCODAMOL; MORPHINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TRAMADOL;

ADULT; ADVANCED CANCER; AGED; ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; BEDTIME DOSAGE; CANCER PAIN; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHIC PAIN; PAIN ASSESSMENT; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; RATING SCALE; SOMNOLENCE; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; PAIN;

EID: 44849096697     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269216308088692     Document Type: Article

References (33)

1. Hanks, G, Cherny, NI, Fallon, M. Opioid analgesic therapy. In: Doyle, D, Hanks, G, Cherny, NI, et al, (eds), Oxford textbook of palliative medicine, 3rd ed. Oxford: Oxford University Press; 2004. p. 316-341.
2. World Health Organization. Cancer pain relief. Geneva: World Health Organization; 1986.
3. World Health Organization. Cancer pain relief, 2nd ed. Geneva: World Health Organization; 1996.
4. World Health Organization. Model list of essential drugs (EDL), 11th ed. www.who.int/medicines/organization/par/edl/infed111group.litml; 1999.
5. Hanks, GW, DeConno, F, Ripamonti, C, Ventafridda, V, Hanna, M, McQuay, HJ, Mercadante, L, et al. Morphine in cancer pain: modes of administration. BMJ 1996; 312: 823-826.
6. Hanks, GW, DeConno, F, Cherny, N, Hanna, M, Kalso, E, McQuay, HJ, Mercadante, L, et al. Morphine and alternative opioids in cancer pain: The EAPC recommendations. Br J Cancer 2001; 84: 587-593.
7. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology™. http://www.nccn.org/professionals/ physician_gls/default.asp; [accessed 13.06.07].
8. Guide to the use of Medicines based on British National Formulary, Cap 1, Par 1.3.1 Dolore; 2005 N 3. http://www.guidausofarmaci.it.
9. Mercadante, S, Radbruch, L, Caraceni, A, Cherney, N, Kaasa, S, Nauch, F, et al. Episodic (Breakthrough) pain. Consensus Conference of an Expert Working Group of the European Association for Palliative Care. Cancer 2002; 94: 832-839.
10. World Health Organization. WHO's pain relief ladder. http://www.who.int/ cancer/palliative/painladder/en/; 2007 [accessed 12.06.07].
11. Joint Formulary Committee. British National Formulary, 53rd ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2007.
12. Regnard, CF, Badger, C. Opioids, sleep and the time of death. Palliat Med 1987; 1: 107-110.
13. Klepstad, P, Kaasa, S, Cherny, N, Hanks, GW, De Conno, F, Research Steering Comimitee of EAPC. Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med 2005; 19: 477-484.
14. De Conno, F, Ripamonti, C, Brunelli, C. Opioid purchases and expenditure in nine western European countries. "Are we killing off morphine?". Palliat Med 2005; 19: 179-184.
15. Chinellato, A, Terrazzani, G, Walley, T, Giusti, P. Opioids in Italy: is marketing more powerful than the law? Lancet 2003; 362: 78.
16. Ripamonti, C, Fagnoni, E, Campa, T, Brunelli, C, De Conno, F. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support Care Cancer 2006; 14: 400-407.
17. Janssen, LP. Important drug warning [US Food and Drug Administration Web site]. http://www.fda.gov/medwatch/SAFETY/2005/duragesic.ddl.pdf; 2005 [accessed 12.06.07].
18. Mattews, JNS, Altman, DG, Campbell, MJ, Royston, P. Analysis of serial measurements in medical research. BMJ 1990; 300: 230-235.
19. Sawe, J, Dahlstrom, B, Paalzow, L, Rane, A. Morphine kinetics in cancer patients. Clin Pharmacol Ther 1981; 30: 629-635.
20. Hoskin, PJ, Hanks, GW, Aherne, GW, Chapman, D, Littleton, P, Filshie, J, et al. The bioavailability of and pharmacokinetics of morphine after intravenous, oral and buccal administration in health volunteers. Br J Clin Pharmacol 1989; 27: 499-505.
21. Gourlay, GK, Plummer, JL, Cherry, DA, Purser, T. The reproducibility of bioavailability of oral morphine from solution under fed and fasted conditions. J Pain Symptom Manage 1991; 6: 431-436.
22. Cherny, N, Ripamonti, C, Pereira, J, Davis C,, Fallon, M, McQuay, H, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001; 19: 2542-2554.
23. Grond, S, Zech, D, Diefenbach, C, Radbruch, L, Lehmann, KA. Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain 1996; 64: 107-114.
24. Caraceni, A, Portenoy, RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 1999; 82: 263-274.
25. Ashby, MA, Fleming, BG, Brooksbank, M, Rounsefell, B, Runciman, WB, Jackson, K, et al. Description of a mechanistic approach to pain management in advanced cancer. Preliminary report. Pain 1992; 51: 153-161.
26. Zeppetella, G, O'Doherty, CA, Collins, S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 2001; 21: 87-92.
27. Swanwick, M, Haworth, M, Lennard, RF. The prevalence of episodic pain in cancer: a survey of hospice patients on admission. Palliat Med 2001; 15: 9-18.
28. Fortner, BV, Okon, TA, Portenoy, RK. A. survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 2002; 3: 38-44.
29. Hwang, SS, Chang, VT, Kasimis, B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003; 101: 55-64.
30. Banning, A, Sjørgen, P, Henriksen, H. Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 1991; 45: 45-48.
31. Portenoy, RK, Hagen, NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41: 273-281.
32. Fine, PG, Busch, MA. Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage 1998; 16: 179-183.
33. Zenz, M, Willweber-Strumpf, A. Opiophobia and cancer pain in Europe. Lancet 1993; 341: 1075-1076.